Zoetis Inc.


SKU: ZTS Category:


This is our first report on animal health pharma major, Zoetis. Despite the world’s volatile external environment and economic unpredictability, Zoetis has performed well from a financial standpoint given to its varied durable portfolio and global reach. However, the last quarter was not great and the company produced disappointing results failing to meet Wall Street expectations in terms of revenues as well as earnings. It delivered a 5% operating revenue increase in Q3, which reflected a decent yet below-par performance across its range of innovation-driven companion animal products, particularly in its overseas markets. Supply issues throughout the year continue to be a barrier to satisfying global demand, and their effects were particularly noticeable in the third quarter. In some product categories, such as parasiticides, supply has been increasing, and they continue to provide supply for essential goods and markets a priority. Besides, their pet care products are increasingly helping to fuel growth in some of their biggest markets, like China and Australia. They also expect a high global demand for novel goods, particularly in companion animal parasiticides, dermatology, vaccines, diagnostics, and monoclonal antibodies for pain. We have faith in Zoetis’s ability to withstand the challenges regarding supply restrictions, generic competition, and the macroeconomic uncertainty present. We initiate coverage on the stock of Zoetis with a ‘Buy’ rating.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!